Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does NATALIZUMAB Cause Multiple fractures? 19 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 19 reports of Multiple fractures have been filed in association with NATALIZUMAB (TYRUKO). This represents 0.0% of all adverse event reports for NATALIZUMAB.

19
Reports of Multiple fractures with NATALIZUMAB
0.0%
of all NATALIZUMAB reports
2
Deaths
15
Hospitalizations

How Dangerous Is Multiple fractures From NATALIZUMAB?

Of the 19 reports, 2 (10.5%) resulted in death, 15 (78.9%) required hospitalization.

Is Multiple fractures Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for NATALIZUMAB. However, 19 reports have been filed with the FAERS database.

What Other Side Effects Does NATALIZUMAB Cause?

Multiple sclerosis relapse (6,478) Fatigue (4,456) Multiple sclerosis (4,078) Memory impairment (3,024) Malaise (2,523) Fall (2,481) Headache (2,476) Gait disturbance (2,427) Prescribed underdose (2,162) Maternal exposure during pregnancy (1,948)

What Other Drugs Cause Multiple fractures?

EMTRICITABINE\TENOFOVIR DISOPROXIL (8,088) TENOFOVIR DISOPROXIL (6,793) EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL (4,102) COBICISTAT\ELVITEGRAVIR\EMTRICITABINE\TENOFOVIR DISOPROXIL (1,942) EMTRICITABINE\RILPIVIRINE\TENOFOVIR DISOPROXIL (1,489) DENOSUMAB (415) NEXIUM (346) ADALIMUMAB (305) ETANERCEPT (251) ABATACEPT (217)

Which NATALIZUMAB Alternatives Have Lower Multiple fractures Risk?

NATALIZUMAB vs NATALIZUMAB-SZTN NATALIZUMAB vs NATAMYCIN NATALIZUMAB vs NATEGLINIDE NATALIZUMAB vs NAVITOCLAX NATALIZUMAB vs NAXITAMAB-GQGK

Related Pages

NATALIZUMAB Full Profile All Multiple fractures Reports All Drugs Causing Multiple fractures NATALIZUMAB Demographics